Big News: Teva Pharmaceutical Industries, J.C. Penney Company, Mattel, AbbVie Inc

Publishing & Media

Share Tweet

Big News: Teva Pharmaceutical Industries, J.C. Penney Company, Mattel, AbbVie Inc

NEW YORK, April 17, 2013 -, one of the leaders in providing investment alerts on U.S. stocks are announcing Investment Highlights on Teva Pharmaceutical Industries, J.C. Penney Company, Mattel, AbbVie Inc.

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock fell 0.03% to $38.64. The company s reducing manufacturing operations as part of a cost-cutting effort, though most of the savings under the plan will come
from lowering procurement expenses, Chief Executive Officer Jeremy Levin said on April 11.

Has TEVA Reached The Bottom and Ready To Move higher? Find Out Here (OR Just copy and paste the link)

Teva has set a goal of lowering expenses by as much as $2 billion over five years to increase long-term profitability. The plan m ay lead to job losses in Israel, where Teva is the largest company by market value, Ronny Gal, an analyst at Sanford C. Bernstein & Co., said last month.

J.C. Penney Company, Inc.(NYSE:JCP) shares dropped 2.96% to $14.74.  The company has hired the financial advisory arm of Blackstone Group LP as it explores ways to bolster its balance sheet, a source familiar with the matter said on April 11. The ailing retailer is seeking to raise about $1 billion in cash, according to the Wall Street Journal, which reported the news earlier.

Is JCP a Buy After The Recent Plunge? Get Free Trend Analysis Here (OR Just copy and paste the link)

Additionally, the company, on Mar. 27, said it had resumed a marketing strategy of raising prices and then discounting them on its own brands in a move to protect profit margins and win back the bargain-conscious
shoppers it lost last year.

Mattel, Inc. (NASDAQ:MAT) shares gained 4.09% to $44.74. The company on April 17, reported that its first-quarter profit surged nearly five times from last year, benefited by strong performance in its girls' brands.

How Should Investors Trade MAT After Today’s solid Earnings? Get Free Report Here (OR Just copy and paste the link)

The company posted a first quarter net income of $38.5 million or $0.11 per share from last year's $7.8 million or $0.02 per share. Analysts expected earnings of $0.09 per share for the quarter. Quarterly net sales grew 7 percent to $995.6 million from prior year's $928.4 million, and beat consensus estimates of $985.79 million.

AbbVie Inc (NYSE:ABBV) shares fell 2.33% to $41.46. The company on April 16 said it will fire its sales force for heart drugs as the medicines lose patent protection and face generic competition, according to a person familiar with the matter.

Is ABBV a Buy After The Recent development? Get Free Report Here (OR Just copy and paste the link)

The company is shifting its focus from primary care, such as drugs that treat a patient’s cholesterol, stroke or diabetes, to so-called specialty medications in areas of unmet health needs, Chief Financial Officer
William Chase said in January.

About is a subscription-based investment newsletter that provides regular coverage, analysis, and commentary on Nasdaq, Pink Sheets and OTCBB Stocks.  Subscribers receive intra-day stock analysis and commentary, as well as access to our regular Special Reports, and Trading Tools.
Disclaimer is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. is a wholly owned entity of a financial public relations firm.  We have not been compensated by any of the companies listed in this news release.

1419 Westwood Blvd Los
Angeles, CA
[email protected]